Journals

• de Boer, S., Powell, M., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P., Ledermann, J., Do, V., Khaw, P., et al (2018). Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology, 19(3), 295-309. [More Information]
• Flower, E., Do, V., Sykes, J., Dempsey, C., Holloway, L., Summerhayes, K., Thwaites, D. (2017). Deformable image registration for cervical cancer brachytherapy dose accumulation: Organ at risk dose-volume histogram parameter reproducibility and anatomic position stability. Brachytherapy, 16(2), 387-392. [More Information]
• Vinod, S., Lim, K., Bell, L., Veera, J., Ohanessian, L., Juresic, E., Borok, N., Chan, P., Chee, R., Do, V., et al (2017). High-risk CTV delineation for cervix brachytherapy: Application of GEC-ESTRO guidelines in Australia and New Zealand. Journal of Medical Imaging and Radiation Oncology, 61(1), 133-140. [More Information]
• Morris, L., Do, V., Chard, J., Brand, A. (2017). Radiation-induced vaginal stenosis: current perspectives. International Journal of Women's Health, 9, 273-279. [More Information]
• Shetty, D., Loh, H., Bui, C., Mansberg, R., Hadjashrafi, A., Do, V. (2016). Non-Prostate-Specific Membrane Antigen-Avid Metastatic Lung Nodule From Primary Prostatic Adenocarcinoma. Clinical Nuclear Medicine, 41(10), 776-778. [More Information]
• Jameson, M., McNamara, J., Bailey, M., Metcalfe, P., Holloway, L., Foo, K., Do, V., Mileshkin, L., Creutzberg, C., Khaw, P. (2016). Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. Journal of Medical Imaging and Radiation Oncology, 60(4), 554-559. [More Information]
• Jacob, S., Ng, W., Do, V. (2015). Estimation of an Optimal Chemotherapy Utilisation Rate for Cancer: Setting an Evidence-based Benchmark for Quality Cancer Care. Clinical Oncology, 27(2), 77-82. [More Information]
• Ng, W., Jacob, S., Delaney, G., Do, V., Barton, M. (2015). Estimation of an optimal chemotherapy utilisation rate for upper gastrointestinal cancers: setting an evidence-based benchmark for the best-quality cancer care. Gastroenterology Research and Practice, 2015, 1-10. [More Information]
• Brand, A., Do, V., Stenlake, A. (2012). Can an Educational Intervention Improve Compliance With Vaginal Dilator Use in Patients Treated With Radiation for a Gynecological Malignancy? International Journal of Gynecological Cancer, 22(5), 897-904. [More Information]
• Wang, W., Do, V., Hogg, R., Wain, G., Brand, A., Bull, C., Stenlake, A., Gebski, V. (2009). Uterine papillary serous carcinoma: patterns of failure and survival. Australian and New Zealand Journal of Obstetrics and Gynaecology, 49(4), 419-425. [More Information]
• Koh, E., Do, V., Barton, M. (2008). Frontiers of cancer care in Asia-Pacific region: cancer care in Australia. Biomedical Imaging and Intervention Journal: a multidisciplinary, 4(3), e30-e30. [More Information]
• Hindson, B., Turner, S., Do, V. (2007). Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancer. Journal of Medical Imaging and Radiation Oncology, 51(6), 584-588. [More Information]
• Holmes-Walker, J., Woo, H., Gurney, H., Do, V., Chipps, D. (2006). Maintaining bone health in patients with prostate cancer. Medical Journal of Australia, 184(4), 176-179. [More Information]

2018

• de Boer, S., Powell, M., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P., Ledermann, J., Do, V., Khaw, P., et al (2018). Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology, 19(3), 295-309. [More Information]

2017

• Flower, E., Do, V., Sykes, J., Dempsey, C., Holloway, L., Summerhayes, K., Thwaites, D. (2017). Deformable image registration for cervical cancer brachytherapy dose accumulation: Organ at risk dose-volume histogram parameter reproducibility and anatomic position stability. Brachytherapy, 16(2), 387-392. [More Information]
• Vinod, S., Lim, K., Bell, L., Veera, J., Ohanessian, L., Juresic, E., Borok, N., Chan, P., Chee, R., Do, V., et al (2017). High-risk CTV delineation for cervix brachytherapy: Application of GEC-ESTRO guidelines in Australia and New Zealand. Journal of Medical Imaging and Radiation Oncology, 61(1), 133-140. [More Information]
• Morris, L., Do, V., Chard, J., Brand, A. (2017). Radiation-induced vaginal stenosis: current perspectives. International Journal of Women's Health, 9, 273-279. [More Information]

2016

• Shetty, D., Loh, H., Bui, C., Mansberg, R., Hadjashrafi, A., Do, V. (2016). Non-Prostate-Specific Membrane Antigen-Avid Metastatic Lung Nodule From Primary Prostatic Adenocarcinoma. Clinical Nuclear Medicine, 41(10), 776-778. [More Information]
• Jameson, M., McNamara, J., Bailey, M., Metcalfe, P., Holloway, L., Foo, K., Do, V., Mileshkin, L., Creutzberg, C., Khaw, P. (2016). Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. Journal of Medical Imaging and Radiation Oncology, 60(4), 554-559. [More Information]

2015

• Jacob, S., Ng, W., Do, V. (2015). Estimation of an Optimal Chemotherapy Utilisation Rate for Cancer: Setting an Evidence-based Benchmark for Quality Cancer Care. Clinical Oncology, 27(2), 77-82. [More Information]
• Ng, W., Jacob, S., Delaney, G., Do, V., Barton, M. (2015). Estimation of an optimal chemotherapy utilisation rate for upper gastrointestinal cancers: setting an evidence-based benchmark for the best-quality cancer care. Gastroenterology Research and Practice, 2015, 1-10. [More Information]

2012

• Brand, A., Do, V., Stenlake, A. (2012). Can an Educational Intervention Improve Compliance With Vaginal Dilator Use in Patients Treated With Radiation for a Gynecological Malignancy? International Journal of Gynecological Cancer, 22(5), 897-904. [More Information]

2009

• Wang, W., Do, V., Hogg, R., Wain, G., Brand, A., Bull, C., Stenlake, A., Gebski, V. (2009). Uterine papillary serous carcinoma: patterns of failure and survival. Australian and New Zealand Journal of Obstetrics and Gynaecology, 49(4), 419-425. [More Information]

2008

• Koh, E., Do, V., Barton, M. (2008). Frontiers of cancer care in Asia-Pacific region: cancer care in Australia. Biomedical Imaging and Intervention Journal: a multidisciplinary, 4(3), e30-e30. [More Information]

2007

• Hindson, B., Turner, S., Do, V. (2007). Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancer. Journal of Medical Imaging and Radiation Oncology, 51(6), 584-588. [More Information]

2006

• Holmes-Walker, J., Woo, H., Gurney, H., Do, V., Chipps, D. (2006). Maintaining bone health in patients with prostate cancer. Medical Journal of Australia, 184(4), 176-179. [More Information]